Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11127938 | 0.88 | KMT2A (0.43) | AAK1KMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL11127941 | 0.88 | KMT2A (0.43) | AAK1KMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL11114111 | 0.88 | AAK1 (0.50) | AAK1KMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL11112454 | 0.88 | AAK1 (0.46) | AAK1SMN1; SMN2TDP1ALDH1A1POLB | |
| SCHEMBL11315574 | 0.87 | MEN1 (0.42) | AAK1KMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL14493754 | 0.85 | AAK1 (0.54) | AAK1KMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL16119506 | 0.83 | AAK1 (0.43) | AAK1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL14879796 | 0.83 | AAK1 (0.43) | AAK1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL5928301 | 0.82 | MEN1 (0.51) | AAK1KMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL11118461 | 0.81 | AAK1 (0.51) | AAK1KMT2AMEN1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421058-B1 | PROCESSES FOR THE PRODUCTION OF ALPHA-DIFLUOROMETHYL ORNITHINE (DFMO) | SKINMEDICA INC (US) | 2010-05-05 | — | — | EP | disclosed |
| US-7012158-B2 | Processes for the production of α-difluoromethyl ornithine (DFMO) | SKINMEDICA, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1421058-A4 | PROCESSES FOR THE PRODUCTION OF ALPHA-DIFLUOROMETHYL ORNITHINE (DFMO) | SKINMEDICA INC (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040171876-A1 | Processes for the production of alpha-difluoromethyl ornithine (DFMO) | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-02 | — | — | US | disclosed |
| EP-1421058-A2 | PROCESSES FOR THE PRODUCTION OF ALPHA-DIFLUOROMETHYL ORNITHINE (DFMO) | Women First Healthcare, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6730809-B2 | FORMED VIA CHEMICAL REDUCTION AND HYDROLYSIS WITH MINIMAL USE OF HALOGENATED SOLVENTS; COMPRISES USE OF INTERMEDIATES SUCH AS ETHYL 2-BENZYLIDENEAMINO-2-DIFLUOROMETHYL-4-CYANOBUTANOATE | WOMEN FIRST HEALTHCARE, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20030083384-A1 | Processes for the production of alpha-difluoromethyl ornithine (DFMO) | BRISTOL-MYERS SQUIBB COMPANY TO WOMEN FIRST HEALTHCARE, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003020209-A2 | PROCESSES FOR THE PRODUCTION OF ALPHA-DIFLUOROMETHYL ORNITHINE (DFMO) | WOMEN FIRST HEALTHCARE, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-0047516-B1 | PROPYLAMINE DERIVATIVE AND PROCESS OF MANUFACTURING THE SAME | TORAY INDUSTRIES, INC. (JP) | 1984-01-04 | — | — | EP | disclosed |
| EP-0047516-A1 | Propylamine derivative and process of manufacturing the same | TORAY INDUSTRIES, INC. (JP) | 1982-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171876-A1 | Processes for the production of alpha-difluoromethyl ornithine (DFMO) | ODC1, OTC, OAT | AAK1 1849/4885KMT2A 1917/4885MEN1 1364/4885 |
| US-20030083384-A1 | Processes for the production of alpha-difluoromethyl ornithine (DFMO) | ODC1, OTC, OAT | AAK1 1849/4885KMT2A 1917/4885MEN1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.